Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test
Open Access
- 22 March 2011
- journal article
- Published by Public Library of Science (PLoS) in PLoS Currents
- Vol. 3, RRN1220
- https://doi.org/10.1371/currents.rrn1220
Abstract
Colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths in the United States. Screening has been shown to be effective in reducing colorectal cancer incidence and mortality. Colonoscopy, sigmoidoscopy, and fecal occult blood tests are all recommended screening tests that have widespread availability. Nevertheless, many people do not receive the evidence-based recommended screening for colorectal cancer. Additional stool-based methods have been developed that offer more options for colorectal cancer screening, including a variety of fecal DNA tests. The only fecal DNA test that is currently available commercially in the United States is ColoSure(TM), which is marketed as a non-invasive test that detects an epigenetic marker (methylated vimentin) associated with colorectal cancer and pre-cancerous adenomas. We examined the published literature on the analytic validity, clinical validity, and clinical utility of ColoSure and we briefly summarized the current colorectal cancer screening guidelines regarding fecal DNA testing. We also addressed the public health implications of the test and contextual issues surrounding the integration of fecal DNA testing into current colorectal cancer screening strategies. The primary goal was to provide a basic overview of ColoSure and identify gaps in knowledge and evidence that affect the recommendation and adoption of the test in colorectal cancer screening strategies.Keywords
This publication has 33 references indexed in Scilit:
- DNA methylation and cancer: ghosts and angels above the genesCurrent Opinion in Oncology, 2011
- Longitudinal Adherence With Fecal Occult Blood Test Screening in Community PracticeAnnals of Family Medicine, 2010
- Effect of Verification Bias on the Sensitivity of Fecal Occult Blood Testing: a Meta-AnalysisJournal of General Internal Medicine, 2010
- Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future ratesCancer, 2009
- Sensitive digital quantification of DNA methylation in clinical samplesNature Biotechnology, 2009
- Genomic and Epigenetic Instability in Colorectal Cancer PathogenesisGastroenterology, 2008
- Highly Methylated Genes in Colorectal Neoplasia: Implications for ScreeningCancer Epidemiology, Biomarkers & Prevention, 2007
- Faecal screening of colorectal cancerInternational Journal of Clinical Practice, 2007
- A Novel Method to Capture Methylated Human DNA from Stool: Implications for Colorectal Cancer ScreeningClinical Chemistry, 2007
- Patient perceptions of stool-based DNA testing for colorectal cancer screeningAmerican Journal of Preventive Medicine, 2005